Circle Pharma, a spinout of UCSF and UC Santa Cruz, has collected series B funding from investors including another UC campus, Berkeley.

Shanghai Jin Jiang and Legend Capital could hypothetically lose out, after a letter from SoftBank raised doubts over an agreed $3bn share tender.

Eli Lilly took part in an $80.3m round that pushed chronic illness drug developer Sigilon Therapeutics' overall funding to nearly $200m.

Strategic partner Lyell Immunopharma led a $45m round for Eureka Therapeutics, which will use the money to advance a pipeline that includes a treatment for liver cancer.

The accelerator has formed a task force to fight Covid-19, drawing on the resources of faculty, portfolio companies, doctors and the wider medical community.

Existing backer ShangPharma reinvested in a series B round for the Pfizer-backed macrocyclic peptide drug developer.

Huya, NTT Docomo Ventures and Samsung Ventures have provided a $6m extension for the livestreaming monetisation platform's latest round.

Wayra-backed Quit Genius has secured series A funding as it prepares to add alcohol and drug options to its digital smoking and vaping cessation products.

Point-of-sale system developer Bypass Mobile has been acquired for an undisclosed amount having raised at least $3.5m from backers including eBay and AEG.

SAP.io and existing investor Nvidia both contributed as the speech recognition technology developer nabbed funding in a series A round.